MYH16

Across TCGA pan-cancer cohorts, MYH16 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated MYH16 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher MYH16 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MYH16 expression acts as an unfavorable survival marker.

ESCA and MESO are the cancer types where MYH16 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	All	0.116	0.704	<.001	18	view →
MESO	DFS	Median	III,IV	0.078	0.376	.012	9	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

MYH16–ESCA (OS)

Open the ESCA breakdown →